Tienhaara A, Remes K, Pelliniemi T T
Department of Clinical Chemistry, Turku University Central Hospital, Finland.
Br J Haematol. 1991 Mar;77(3):335-8. doi: 10.1111/j.1365-2141.1991.tb08580.x.
Serum beta 2-microglobulin (beta 2m) levels were followed in eight patients with multiple myeloma who were treated with leucocyte alpha interferon (alpha IFN) 6 x 10(6) IU daily for 1-2 weeks before chemotherapy. Serial measurements of serum beta 2m were carried out regularly during the first week on alpha IFN. A rise in beta 2m was observed in all patients. with maximum increments ranging from 29% to 185% (mean 109%). The increase in beta 2m was most marked in patients with elevated pretreatment levels of serum beta 2m and creatinine. In six patients the peak value was reached between the third and the fifth day, after which the levels decreased. In two patients serum beta 2m remained elevated for 3 and 4 months, respectively. A marked increase in serum beta 2m can be induced by alpha IFN in myeloma, which should be taken into consideration when using beta 2m for the assessment of tumour response during alpha IFN therapy.
对8例多发性骨髓瘤患者在化疗前给予白细胞α干扰素（α IFN）6×10⁶ IU/d，治疗1 - 2周，观察血清β2 - 微球蛋白（β2m）水平。在使用α IFN的第一周定期对血清β2m进行连续测定。所有患者均观察到β2m升高，最大增幅为29%至185%（平均109%）。血清β2m升高在治疗前血清β2m和肌酐水平升高的患者中最为明显。6例患者在第3天至第5天达到峰值，之后水平下降。2例患者血清β2m分别持续升高3个月和4个月。α IFN可诱导骨髓瘤患者血清β2m显著升高，在使用β2m评估α IFN治疗期间的肿瘤反应时应予以考虑。
